TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02456207
Drug: SCT400
Normalized name: Immunoglobulin igg1, anti-(human cd20 antigen) (human-mus musculus monoclonal disulfide sct400 .gamma.1-chain), disulfide with human-mus musculus monoclonal sct400 .kappa.-chain, dimer
DrugBank: Ripertamab (DB16314)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02456207
Drug: Rituximab
Normalized name: Rituximab
DrugBank: Rituximab (DB00073)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT02611037
Drug: Cisplatin
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The recommended dose of cisplatin for transarterial chemoperfusion in this study is 35 mg/m\^2 body surface area (BSA). During the lead in phase of the study, 3 patients will be treated with regular doses of cisplatin.
Study: NCT00301145
Drug: varenicline
Normalized name: Varenicline
DrugBank: Varenicline (DB01273)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02644252
Drug: Day 1: Cisplatin 75 mg/m2
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02644252
Drug: Day 1: Vinorelbine 25 mg/m2
DrugBank: Vinorelbine (DB00361)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02644252
Drug: Day 8: Capsule vinorelbine 50 mg/m2
DrugBank: Vinorelbine (DB00361)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02644252
Drug: Day 1: Carboplatin AUC=5
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT02644252
Drug: Day 1: Vinorelbine 30 mg/m2
DrugBank: Vinorelbine (DB00361)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02644252
Drug: Day 8: Capsule vinorelbine 60 mg/m2
DrugBank: Vinorelbine (DB00361)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT03171584
Drug: Terbinafine
Normalized name: Terbinafine
DrugBank: Terbinafine (DB00857)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: oral antifungal drugs
Study: NCT00819000
Drug: Glatiramer Acetate, IFN-beta 1a (IM), IFN-beta 1a (Subcutaneous), and IFN-beta 1b
DrugBank: Glatiramer (DB05259)
Approvals — FDA: no, EMA: no, PMDA: no
Description: MS therapies (listed above) used according to prescribers' instructions.
Study: NCT03637361
Drug: REL-1017
Normalized name: (2R*,3S)-rel-1,2,3,4-butanetetroltetranitrate
DrugBank: Erythrityl tetranitrate (DB01613)
Approvals — FDA: no, EMA: no, PMDA: no
Description: The investigational product, REL-1017 is prepared as a solution with Ocean Spray® Diet Cranberry Juice on site to obtain a final volume of 100 mL for dosing. The study drug will be administered as a solution of 5 mg, 20 mg, 60 mg, 100 mg, 150 mg or 200 mg REL-1017, based on randomization prepared in Ocean Spray® Diet Cranberry Juice with a final volume of 100 mL
Study: NCT00438360
Drug: Cyclosporine A microemulsion
Normalized name: cyclosporine microemulsion
DrugBank: Cyclosporine (DB00091)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral soft gelatin capsules of Cyclosporine 10 mg, 25 mg, 50 mg or 100 mg administered twice a week for 24 weeks at the dosage of 5 mg/Kg/day in two daily administrations
Study: NCT01309997
Drug: imatinib mesylate
Normalized name: Imatinib Mesylate
DrugBank: Imatinib (DB00619)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Given PO
Study: NCT02583633
Drug: Transdermal nitroglycerin
Normalized name: nitroglycerin Transdermal System
DrugBank: Nitroglycerin (DB00727)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02583633
Drug: nifedipine
Normalized name: Nifedipine
DrugBank: Nifedipine (DB01115)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02029456
Drug: 25 mg Actilyse ( Boehringer Ingelheim, Germany) infusion in 6 hours
Normalized name: activated charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02691910
Drug: Chloroquine
Normalized name: Chloroquine
DrugBank: Chloroquine (DB00608)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 10mg/kg on day 0 and 7.5mg/kg on days 1 and 2. Total dose, 25 mg base/kg. Tablet containing 150mg of base.
Study: NCT02691910
Drug: Primaquine
Normalized name: Primaquine
DrugBank: Primaquine (DB01087)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 0.5 mg/kg once a day, for seven days. Total dose, 3.5mg/kg.
Study: NCT01231334
Drug: Dapsone plus Adapalene
Normalized name: Dapsone
DrugBank: Adapalene (DB00210)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dapsone (Aczone® Gel 5%) applied to entire face in the morning. Adapalene (Differin® 0.3% Gel)followed by Dapsone (Aczone® Gel 5%) applied to entire face in the evening. Daily treatment for 12 weeks.
Study: NCT02173639
Drug: BI 1356/metformin
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: fixed dose combination tablet
Study: NCT02173639
Drug: BI 1356
Normalized name: BI 2536
DrugBank: BI 2536 (DB16107)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00641407
Drug: Insulin glargine
Normalized name: Insulin Glargine
DrugBank: Insulin glargine (DB00047)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 10 IU bedtime and then titration
Study: NCT02173639
Drug: Metformin
Normalized name: Metformin
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT00304616
Drug: Aripiprazole, Solian, Olanzapine, Seroquel, Risperidone
DrugBank: Olanzapine (DB00334)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00588237
Drug: Paclitaxel,Cisplatin, Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: IV paclitaxel, followed by IV Bevacizumab on Day 1. Bevacizumab treatment will begin cycle 2, day 1. IP cisplatin will be given on Day 2, and IP Paclitaxel on Day 8. Subjects will receive up to six cycles of therapy, or until disease progression or unacceptable toxicity.
Study: NCT00418132
Drug: Thalidomide
Normalized name: Thalidomide
DrugBank: Thalidomide (DB01041)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Thalidomide at a dose of 50 mg/day. The dose will be increased to 100 mg/day at Week 2, then to 200 mg/day at Week 4, and finally to 300 mg/day at Week 6.
Study: NCT00418132
Drug: Placebo thalidomide
Normalized name: Thalidomide
DrugBank: Thalidomide (DB01041)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Participants will receive placebo thalidomide. The placebo dose will be increased through to Week 6.
Study: NCT03272477
Drug: Goserelin
Normalized name: Goserelin
DrugBank: Goserelin (DB00014)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 3,6mg every 28 days or 4 weeks in pre-menopausal women treated with aromatase inhibitors Anastrozole or Letrozole or Exemestane, for a total of 40 weeks in the adjuvant therapy phase.
Study: NCT02912234
Drug: Apixaban
Normalized name: Apixaban
DrugBank: Apixaban (DB06605)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Multiple-dose clarithromycin and single-dose Apixaban
Study: NCT03216447
Drug: Advagraf
Normalized name: Astagraf
DrugBank: Tacrolimus (DB00864)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tacrolimus prolonged-release hard capsules (QD)
Study: NCT03216447
Drug: Prograf
Normalized name: Prograf
DrugBank: Tacrolimus (DB00864)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tacolimus capsules (q12h)
Study: NCT01296256
Drug: Bendamustine-EAM
DrugBank: Bendamustine (DB06769)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Bendamustine 200 mg/m2 starting dose on day -7 and -6 Etoposide 200 mg/m2 from day -5 to day -2 Ara-C 400 mg/m2 from day -5 to day -2 Melphalan 140 mg/m2 on day -1
Study: NCT03272477
Drug: Anastrozole
Normalized name: Anastrozole
DrugBank: Anastrozole (DB01217)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 1mg per day for 12 weeks in neoadjuvant therapy phase; 1mg per day for a total of 40 weeks max. in adjuvant therapy phase
Study: NCT02096952
Drug: Methylphenidate extended-release liquid formulation
Normalized name: methylphenidate Extended Release Suspension
DrugBank: Methylphenidate (DB00422)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02350335
Drug: Nicotine (transdermal)
Normalized name: Nicotine
DrugBank: Nicotine (DB00184)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Application of transdermal nicotine replacement in smokers with acute aneurysmal hemorrhage
Study: NCT00372619
Drug: clofarabine
Normalized name: Clofarabine
DrugBank: Clofarabine (DB00631)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Given IV for 5 days
Study: NCT00372619
Drug: cytarabine
Normalized name: Cytarabine
DrugBank: Cytarabine (DB00987)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT00437957
Drug: Temozolomide
Normalized name: Temozolomide
DrugBank: Temozolomide (DB00853)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 75 Mg/m2/day for all Cohorts
Study: NCT00437957
Drug: Valproic Acid
Normalized name: Valproic Acid
DrugBank: Valproic acid (DB00313)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cohort 1: 20 mg/kg/day Cohort 2: 30 mg/kg/day Cohort 3: 40 mg/kg/day Cohort 4: 50 mg/kg/day
Study: NCT02684617
Drug: dinaciclib
Normalized name: Dinaciclib
DrugBank: Dinaciclib (DB12021)
Approvals — FDA: no, EMA: no, PMDA: no
Description: dinaciclib 7 mg/m\^2 administered as an IV infusion on Day 1 of infusion Cycle 1, dinaciclib 10 mg/m\^2 administered as an IV infusion on Day 8 of infusion Cycle 1, dinaciclib 14 mg/m\^2 administered as an IV infusion on Days 1 and 8 of infusion Cycles 2-35. Each cycle is 21 days.
Study: NCT00203736
Drug: Sulfadoxine-pyrimethamine
Normalized name: pyrimethamine / sulfadoxine
DrugBank: Pyrimethamine (DB00205)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00203736
Drug: Artesunate plus sulfadoxine-pyrimethamine
Normalized name: pyrimethamine / sulfadoxine
DrugBank: Pyrimethamine (DB00205)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00833963
Drug: Trastuzumab
Normalized name: trastuzumab
DrugBank: Trastuzumab (DB00072)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Participants will receive trastuzumab as determined by their treating physicians' standards of care.
Study: NCT00833963
Drug: Pertuzumab
Normalized name: Pertuzumab
DrugBank: Pertuzumab (DB06366)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Participants will receive pertuzumab as determined by their treating physicians' standards of care.
Study: NCT00833963
Drug: Ado-Trastuzumab Emtansine
Normalized name: Ado-Trastuzumab emtansine
DrugBank: Trastuzumab emtansine (DB05773)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Participants will receive ado-trastuzumab emtansine as determined by their treating physicians' standards of care.
Study: NCT01118403
Drug: Sultamicillin
Normalized name: sultamicillin
DrugBank: Sultamicillin (DB12127)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ampoules per 1.5 grams, three grams intravenously every 6 hours for 4 doses diluted in physiologic Sodium Chloride Solution
Study: NCT04301934
Drug: Conjugated estrogen
Normalized name: Conjugated estrogen
DrugBank: Conjugated estrogens (DB00286)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Current standard treatment for recurrent UTIs in postmenopausal women
Study: NCT00969306
Drug: Chloroquine, A-CQ 100
DrugBank: Chloroquine (DB00608)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Administration:~* Orally~* Timing: Once daily~* Tablets of 100 mg~* During or after meals~* In case of missed dose: intake of the missed dose is still possible up until 12 hours before the next dose.~* Patients should always note date and time of intake on the chloroquine monitoring form.
Study: NCT03248531
Drug: Bimekizumab
Normalized name: bimekizumab
DrugBank: Bimekizumab (DB12917)
Approvals — FDA: no, EMA: yes, PMDA: yes
Description: Bimekizumab in different dosages (dose 1 and 2).
Study: NCT03248531
Drug: Adalimumab
Normalized name: Adalimumab
DrugBank: Adalimumab (DB00051)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Adalimumab in different dosages (dose 1, 2 and 3).
Study: NCT00815568
Drug: fludarabine phosphate, busulfan
DrugBank: Busulfan (DB01008)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Fludarabine ( 30mg/m2, iv, D-7\~D-2) Busulfan (3.2mg/kg, iv, D-6\~D-3) Total body irradiation (200cGy/day, D-2,-1)
Study: NCT01345929
Drug: CXA-201
Normalized name: CXA-10
DrugBank: CXA-10 (DB15026)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CXA-201 IV infusion (1500mg q8) for 7 days
Study: NCT01345929
Drug: Levofloxacin
Normalized name: Levofloxacin
DrugBank: Levofloxacin (DB01137)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Levofloxacin IV infusion (750mg qd) for 7 days
Study: NCT03396497
Drug: Pembrolizumab
Normalized name: Pembrolizumab
DrugBank: Pembrolizumab (DB09037)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Pembrolizumab administered every 3 weeks as prescribed as standard of care by the investigator in accordance with the package insert.
Study: NCT03438708
Drug: Axitinib Oral Tablet [Inlyta]
Normalized name: axitinib Oral Tablet [Inlyta]
DrugBank: Axitinib (DB06626)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Axitinib 5 milligrams (mg) administered orally (po) twice daily (BID) for 8 weeks (with titration to 7 mg BID as tolerated at 4 weeks)
Study: NCT01901614
Drug: Retrobulbar Block or General Anesthesia
Normalized name: Ivy Block
DrugBank: Bentoquatam (DB00516)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00355862
Drug: Sirolimus
Normalized name: Sirolimus
DrugBank: Sirolimus (DB00877)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Sirolimus based immunosuppression
Study: NCT01650649
Drug: Lofexidine HCl
Normalized name: lofexidine HCl
DrugBank: Lofexidine (DB04948)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lofexidine HCl 0.2 mg tablets titrated in ascending doses of 0.2 mg (1 tablet) QID starting at 0.4 mg (2 tablets) QID \[e.g. Day 1 0.4 mg (2 tablets) QID, Day 2 0.6 (3 tablets)QID, etc\] as described in the treatment arm. Option to down-titrate to 0.2 mg (1 tablet) QID if 0.4 mg (2 tablets) QID dose not initially tolerated.
Study: NCT01650649
Drug: Lofexidine-matching sugar pill
Normalized name: lofexidine Pill
DrugBank: Lofexidine (DB04948)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lofexidine-matching sugar pill tablets titrated in ascending doses of 1 tablet starting at 2 tablets QID (e.g. Day 1 2 tablets QID, Day 2 3 tablets QID, etc)as described in the treatment arm. Option to down-titrate to 1 tablet QID if 2 tablets not initially tolerated.
Study: NCT02742233
Drug: saxagliptin
Normalized name: Saxagliptin
DrugBank: Saxagliptin (DB06335)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Qualifying Period: Participants will receive regular treatment for diabetic ulcer without DPP4i.~Treatment Period: Participants will receive saxagliptin with regular treatment
Study: NCT02517996
Drug: Lidocaine
Normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Total 20cc (10cc bilateral) of 1% Lidocaine: Lidocaine is a commonly used anesthetic agent suitable for infiltration, block and surface anesthesia. It is characterized by a rapid onset of action, intermediate duration of efficacy, and its elimination half-life is 90-120 minutes. Lidocaine alters signal conduction in neurons by blocking the fast voltage gated sodium (Na) channels in the neuronal cell membrane that are responsible for signal propagation. With sufficient blockage the membrane of the postsynaptic neuron will not depolarize and will thus fail to transmit an action potential. This creates the anesthetic effect by not merely preventing pain signals from propagating to the brain but by stopping them before they begin. Adverse drug reactions are rare when lidocaine is used as a local anesthetic and when administered correctly.
Study: NCT06238336
Drug: CAR-T cell therapy
Normalized name: Anti-BCMA CAR T cell
DrugBank: Idecabtagene vicleucel (DB16665)
Approvals — FDA: no, EMA: no, PMDA: no
Description: The application of CAR-T therapy in the clinic generally involves the in vitro preparation and in vivo infusion of CAR-T, and the specific experimental process is divided into five steps: (1) isolation of T cells from the peripheral blood of the cancer subjects or single harvested single nucleated cells; (2) use of genetic engineering to transfer CAR structural genes that can specifically recognise the tumour cells into the T cells; (3) in vitro cultivation and expansion of CAR-T cells to the desired infusion dose (4) Non-myeloablative chemotherapy is administered prior to the infusion of CAR-T cells, which is used to remove immunosuppressive cells and reduce the tumour load so as to enhance the efficacy of the treatment; (5) CAR-T cells are infused according to the expected dosage, and the efficacy of the treatment is observed and the adverse reactions are closely monitored.
Study: NCT01841021
Drug: Brentuximab vedotin
Normalized name: Brentuximab Vedotin
DrugBank: Brentuximab vedotin (DB08870)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Brentuximab vedotin will be given by intravenous infusion (into a vein) on Day 1 of every 21 day cycle.
Study: NCT03272477
Drug: Letrozole
Normalized name: Letrozole
DrugBank: Letrozole (DB01006)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 2,5 mg per day for 12 weeks in neoadjuvant therapy phase; 2,5 mg perday for a total of 40 weeks max. in adjuvant therapy phase
Study: NCT02526953
Drug: Paclitaxel
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 45 mg/m2, IV, weekly during the radiation. Number of infusions: 5.
Study: NCT02526953
Drug: Mitomycins
Normalized name: Mitomycin
DrugBank: Mitomycin (DB00305)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 10 mg/m2, IV, on day 1. Number of infusions: 1.
Study: NCT02526953
Drug: Mitomycins
Normalized name: Mitomycin
DrugBank: Mitomycin (DB00305)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 12 mg/m2, IV, on day 1. Number of infusions: 1.
Study: NCT00149799
Drug: Escitalopram
Normalized name: Escitalopram
DrugBank: Escitalopram (DB01175)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: At the end of the initial 14-week phase (open-label escitalopram), participants who responded to open-label escitalopram were randomly assigned to receive escitalopram (same dose as received in Phase I) for an additional 6 months.
Study: NCT03964168
Drug: Biologic Agent
Normalized name: Cytokine-based biologic agent IRX-2
DrugBank: IRX-2 (DB05643)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients who discontinued a bioloic agent
Study: NCT01744067
Drug: Omega-3 fatty acids
Normalized name: Omega-3 Fatty Acids
DrugBank: Omega-3 fatty acids (DB11133)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2,7 g omega-3 fatty acids / day (1 capsule 3 times a day / oral administration)
Study: NCT03034005
Drug: Budesonide
Normalized name: Budesonide
DrugBank: Budesonide (DB01222)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 1600 ug inhaled daily for 6 weeks
Study: NCT00932438
Drug: Oxaliplatin
Normalized name: Oxaliplatin
DrugBank: Oxaliplatin (DB00526)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Oxaliplatin 85 mg/sqm, IV infusion every two weeks
Study: NCT00932438
Drug: 5-Fluorouracil
Normalized name: 5-fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 5-Fluorouracil 2400 mg/sqm, IV infusion every 2 week
Study: NCT00932438
Drug: Bevacizumab
Normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Bevacizumab 5 mg/kg given at the discretion of the treating physician
Study: NCT02833584
Drug: Paracetamol
Normalized name: Paracetamol
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Paracetamol 500 mg x 1 tablets according to patient's body weight
Study: NCT01095991
Drug: Sitagliptin
Normalized name: Sitagliptin
DrugBank: Sitagliptin (DB01261)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Oral tablet od
Study: NCT01628354
Drug: Ranibizumab
Normalized name: Ranibizumab
DrugBank: Ranibizumab (DB01270)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: All patients will receive an intravitreal injection of ranibizumab 0.5 mg at baseline (visit 1; month 0) then a subsequent intravitreal injection at month 1 (visit 2) and month 2 (Visit 3). Patients will be reviewed every month thereafter for 12 months at which time it will be determined whether the patient requires retreatment with ranibizumab 0.5 mg based on measurements of visual acuity, Optical coherene tomography (OCT) findings and clinical appearance. A drop of vision of \>5 letters or increase in retinal thickness of \>100 um on OCT will trigger re-treatment as long as 14 days has elapsed since last treatment.
Study: NCT01939977
Drug: Paricalcitol
Normalized name: Paricalcitol
DrugBank: Paricalcitol (DB00910)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 1 capsule/day for 6 months. On Month 1 and Month 3 it can be increased up to 2 capsules/day or decreased down to 1 capsule/48 hours.
Study: NCT01939977
Drug: Calcifediol
Normalized name: Calcifediol
DrugBank: Calcifediol (DB00146)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 5 drops/day during 6 months. On Month 1 it can be increased up to 7 drops/day. If this occurs then, on Month 3, it can decreased to 5 drops/day or continue 7 drops/day until end of treatment.
Study: NCT01455922
Drug: glimepiride
Normalized name: Glimepiride
DrugBank: Glimepiride (DB00222)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: glimepiride will be up-titrated to 8 mg/day over first 13 weeks
Study: NCT00156104
Drug: Asenapine
Normalized name: Asenapine
DrugBank: Asenapine (DB06216)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 5 mg BID
Study: NCT01880112
Drug: Cefazolin
Normalized name: Cefazolin
DrugBank: Cefazolin (DB01327)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cefazolin will be administered as pre-operative prophylaxis in normal weight patients undergoing Cesarean delivery. Tissue and serum levels will be measured at the time of the incision and when the incision is closed.
Study: NCT00156104
Drug: Asenapine
Normalized name: Asenapine
DrugBank: Asenapine (DB06216)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 10 mg BID
Study: NCT00156104
Drug: Haloperidol
Normalized name: Haloperidol
DrugBank: Haloperidol (DB00502)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 4 mg BID
Study: NCT00004065
Drug: tanespimycin
Normalized name: Tanespimycin
DrugBank: Tanespimycin (DB05134)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00148486
Drug: NS 2330
Normalized name: sodium chloride
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT03532620
Drug: Pitavastatin Calcium
Normalized name: PITAVASTATIN CALCIUM
DrugBank: Pitavastatin (DB08860)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: In Pitavastatin treatment group, Pitavastatin calcium tablet 2mg/day was given for 12 months in combination with lifestyle modification. But month 3 is the check point. If LDL-C target was achieved at Month 3, doses remained the same. If LDL-C target was not achieved at Month 3, doses were doubled.
Study: NCT03532620
Drug: Atorvastatin Calcium
Normalized name: Atorvastatin Calcium
DrugBank: Atorvastatin (DB01076)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: In Atorvastatin treatment group, Atorvastatin calcium tablet 20mg/day was given for 12 months in combination with lifestyle modification. But month 3 is the check point. If LDL-C target was achieved at Month 3, doses remained the same. If LDL-C target was not achieved at Month 3, doses were doubled.
Study: NCT01831466
Drug: tofacitinib ointment 20 mg/g
DrugBank: Tofacitinib (DB08895)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: tofacitinib ointment 20 mg/g BID (twice daily) for 12 weeks
Study: NCT01831466
Drug: tofacitinib ointment 10 mg/g
DrugBank: Tofacitinib (DB08895)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: tofacitinib ointment 10 mg/g BID (twice daily) for 12 weeks
Study: NCT01831466
Drug: tofacitinib ointment 20 mg/g
DrugBank: Tofacitinib (DB08895)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: tofacitinib ointment 20 mg/g QD (once daily) for 12 weeks